Passage Bio is a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no treatment options. The company is leveraging its proprietary gene therapy platform to develop a pipeline of potentially life-changing gene therapies with a focus on rare, monogenic CNS diseases that significantly affect the lives of patients and families. Passage Bio was founded in 2017 and is headquartered in Philadelphia, Pennsylvania.